Another class of antidiabetic drugs with cardioprotective benefits that is used in the treatment of T2DM along with GLP-1 RAs are the SGLT-2i that block SGLT-2-mediated glucose reabsorption in the kidneys, resulting in glycosuria and weight loss [13,15,16,32]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.